Tag: ASCO
Novartis: Presents Leukemia Study at ASCO
(CercleFinance.com) – Novartis’ Scemblix® shows superior long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia study. Novartis presented longer-term follow-up data from the Phase III ASCEMBL study…
Novartis: Presents Leukemia Study at ASCO
(CercleFinance.com) – Novartis’ Scemblix® shows superior long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia study. Novartis presented longer-term follow-up data from the Phase III ASCEMBL study…
Nanobiotix: New attempt to rebound on the stock market for Nanobiotix, highlighted at the ASCO meeting
(BFM Bourse) – The presence of the French specialist in nanomedicine at the largest medical congress dedicated to the fight against cancer (the annual meeting of the American Society for…
Nanobiotix: well geared towards a presentation at ASCO – 06/06/2022 at 11:30 am
(CercleFinance.com) – Nanobiotix climbs 7% after the announcement of the presentation, at the annual meeting of the American Society for Clinical Oncology (ASCO), of new data highlighting the potential of…
Transgene presented new Phase I data of TG4050 at the ASCO 2022 congress – 06/06/2022 at 08:00
Strasbourg, France, June 6, 2022, 8 a.m. – Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops immunotherapies based on viral vectors against cancers, announces that it has…
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022 – 06/06/2022 at 08:00
Strasbourg, France, June 6, 2022, 8:00 am CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that…
Transgene: ‘Promising’ data unveiled at ASCO
Read also (CercleFinance.com) – Transgene shares are on the rise on the Paris Stock Exchange on Monday following the presentation of data deemed ‘promising’ at the annual ASCO cancer conference.…
NOXXON Presents Key Data from Phase 1/2 GLORIA Study Evaluating NOX-A12 in Glioblastoma at ASCO 2022 Annual Meeting – 06/05/2022 at 15:00
To receive all the news in real time from NOXXON, please contact [email protected] Berlin, Germany, June 5, 2022, 3:00 p.m. CEST – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a…
GSK: unveils its latest advances at ASCO
(CercleFinance.com) – GSK will present 25 abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (June 3-7) and nine abstracts at the 2022 European Hematology Association (EHA)…
Ipsen: encouraging data on Cabometyx expected at ASCO
(CercleFinance.com) – Ipsen announces that encouraging data will be presented on its Cabometyx (cabozantinib), for a variety of cancer types at the annual meeting of the American Society of Clinical…
OSE Immunotherapeutics will present four posters on Tedopi®, a combination of neo-epitopes in immuno-oncology, at the ASCO 2022 congress – 05/23/2022 at 18:00
Nantes, France – May 23, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale) announce…
Bayer: to present data at ASCO congress
(CercleFinance.com) – Bayer will present key data across its entire oncology portfolio, illustrating significant advances in cancer treatment, at the ASCO Annual Meeting in 2022. For prostate cancer, the group…